The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review

The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review

Nonalcoholic fatty liver disease (NAFLD) exponentially affects the global healthcare burden, and it is currently gaining increasing interest in relation to its potential impact on central nervous system (CNS) diseases, especially concerning cognitive deterioration and dementias. Overall, scientific...

Full description

Bibliographic Details
Main Authors:	Mauro Giuffrè, Nicola Merli, Maura Pugliatti, Rita Moretti
Format:	Article
Language:	English
Published:	MDPI AG 2024-03-01
Series:	International Journal of Molecular Sciences
Subjects:	NAFLD NASH insulin resistance diabetes gut microbiota inflammation
Online Access:	https://www.mdpi.com/1422-0067/25/6/3337

Similar Items

Role of intestinal flora in the development of nonalcoholic fatty liver disease in children
by: Jing Zhang, et al.
Published: (2024-02-01)

Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy
by: Francesca Fianchi, et al.
Published: (2021-06-01)

Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
by: Sebastião M.B. Duarte, et al.
Published: (2019-05-01)

Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
by: Mijra Koning, et al.
Published: (2023-12-01)

Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Young-Su Yi
Published: (2024-03-01)

Exercise Training as Treatment of Nonalcoholic Fatty Liver Disease
by: Oliver K. Glass, et al.
Published: (2017-09-01)

Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile
by: Helma P. Cotrim, et al.
Published: (2011-01-01)

Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease
by: Plator Memaj, et al.
Published: (2023-07-01)

Pathophysiology of NASH in endocrine diseases
by: Karim Gariani, et al.
Published: (2021-03-01)

SMN Depleted Mice Offer a Robust and Rapid Onset Model of Nonalcoholic Fatty Liver DiseaseSummary
by: Marc-Olivier Deguise, et al.
Published: (2021-01-01)

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
by: Farzaneh Iravani, et al.
Published: (2018-10-01)

Dendritic Cells and T Cell Subsets in the Development of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
by: Gulubova M., et al.
Published: (2021-10-01)

The lipidome in nonalcoholic fatty liver disease: actionable targets
by: Carlos J. Pirola, et al.
Published: (2021-01-01)

The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
by: Roberta Forlano, et al.
Published: (2022-01-01)

Magnetic resonance‐based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Cyrielle Caussy, et al.
Published: (2020-10-01)

Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver DiseaseSummary
by: Leke Wiering, et al.
Published: (2023-01-01)

Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
by: Silvia Sookoian, et al.
Published: (2018-03-01)

Editorial: Advances in non-alcoholic fatty liver disease therapeutics: Pathogenic mechanisms and targets
by: Ana Blas-García, et al.
Published: (2022-11-01)

Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
by: Yuezhi Zhu, et al.
Published: (2023-05-01)

Effects of homocysteine on nonalcoholic fatty liver related disease: A mendelian randomization study
by: Pengcheng Chen, et al.
Published: (2022-12-01)

Implementation of a randomized mobile-technology lifestyle program in individuals with nonalcoholic fatty liver disease
by: Monica A. Tincopa, et al.
Published: (2024-03-01)

SIRT2 Deficiency Aggravates Diet-Induced Nonalcoholic Fatty Liver Disease through Modulating Gut Microbiota and Metabolites
by: Xingyu Li, et al.
Published: (2023-05-01)

Nonalcoholic steatohepatitis in morbid obese patients: coffee consumption vs. disease severity
by: Raffaelle K. Barros, et al.
Published: (2016-05-01)

Correlation of non-alcoholic fatty liver disease and gut microflora: clinical reports and treatment options
by: Pranali A. Jadhav, et al.
Published: (2024-04-01)

Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics
by: Mayumi Nagashimada, et al.
Published: (2021-07-01)

Interplay of Lymphocytes with the Intestinal Microbiota in Children with Nonalcoholic Fatty Liver Disease
by: Tian Liang, et al.
Published: (2022-11-01)

Ferroptosis resistance cooperates with cellular senescence in the overt stage of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
by: Antonella Vetuschi, et al.
Published: (2022-06-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials
by: Joel Yeh Siang Chen, et al.
Published: (2022-12-01)

Detection of patatin-like phospholipase domain-containing protein 3 in nonalcoholic fatty liver disease among egyptian patients
by: Kadry M El Saeed, et al.
Published: (2019-01-01)

Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)
by: Svetlana Spremović Rađenović, et al.
Published: (2022-01-01)

Drug-induced fatty liver disease: An overview of pathogenesis and management
by: Sanjaya K. Satapathy, et al.
Published: (2015-11-01)

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
by: Nicolas Lanthier, et al.
Published: (2022-08-01)

Nonalcoholic fatty liver disease in asymptomatic obese women(a)(a)The work was originated in the Biomedical Research Unit of The Mexican Social Security Institute at Durango, Mex.
by: Heriberto Rodriguez-Hernandez, et al.
Published: (2010-04-01)

Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis
by: Abdulrahman Ismaiel, et al.
Published: (2021-07-01)

Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives
by: Natalia Vallianou, et al.
Published: (2021-12-01)

Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies
by: Somaya Albhaisi, et al.
Published: (2022-11-01)

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction
by: Mingwei Guo, et al.
Published: (2022-02-01)

The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease
by: Dan-dan Cheng, et al.
Published: (2017-05-01)

Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement
by: Lucia Cerrito, et al.
Published: (2023-01-01)